Replies to post #142594 on Cytodyn Inc (CYDY)

[vivamiga]

Such a distortion of facts.
I have looked at the exclusion criteria for the trial. You suggest with your picture that this is a wide range of critical patients. In fact, the criteria exclude only a small proportion of critical patients (e.g. pregnancy). And I have heard very little about pregnant women who have gone critical. In general, they are young. The other exclusion criteria don't seem relevant either. Of course, you want to exclude patients from the trial if there is a risk that they will die the very next day anyway, when the effect of LL doesn't kick in until day 3.
You're assuming a mortality across the range of critical patients of 35%. This may perhaps be the average. The mortality may go up to 80% in the critical patients, depending on which part of the critical patients was included in the trial. I assume that these were only the most critical patients. This is also consistent with the facts we know. SOC got better even though as many patients died in the first 50% as died in the second 50%. This suggests that only a certain cohort of patients was treated where SOC did not improve. CYDY also had an influence on the trial and knows that it is better if only critical patients are enrolled. Therefore, many new trial hospitals were recruited at the end and an expert from CYDY visited the hospitals to advertise. The doctors have certainly not been blind to the condition of the patients and wanted to save the most critical cases first.

[sjacobs26]

Who is this “we” you refer to? I thought you were the single and only expert conducting this precision in-depth statistical analysis of how CD12 is going to be an utter failure? Is Hopester’s chart included in this “we” analysis....he seems to have figured out that leronlimab and CytoDyn are complete scams somehow....must be that 30 June chart interpretation!?

[Blue Man]

Remdesivir does not show statistical significance yet is approved. Primary outcome "all mortality" is still not significant. It was not until doctors practiced what they know is effective to reach SOC today. And research continues to find what might help treat what Remdesivir cannot. That would include leronlimab as a possibility.

Researchers are now testing remdesivir in combination with antibodies and other medications.

Remdesivir also improved mortality rates for those receiving supplemental oxygen (4% with remdesivir versus 13% with placebo at day 29 of treatment). All-cause mortality among all patients was 11% with remdesivir and 15% with placebo at day 29, but this difference between the treatment groups was not large enough to rule out chance. The preliminary findings hadn’t shown an effect on mortality.

https://www.nih.gov/news-events/nih-research-matters/final-report-confirms-remdesivir-benefits-covid-19

[All-Bidness]

Why do we have to wait until Monday? Will the company release news on Monday, or is that when you plan to unveil your FUD when the market is open?

[Itchy palm]

Who is this we think ? More like you and a few also. Where is your proof that trial is bad NP said it would take a couple weeks to read and fill out paperwork on trial wouldn’t that take it till end of next week beginning of February?

[bwolfy2002]

Lol “we”!! This slide is even better than the made up financials one! I’m considering printing it out and breaking out my child’s crayons to add notes.

So how do these “projections” account for the DSMC’s involvement the whole way during CYDY’s trial? Specifically the part where they did NOT end the trial for futility?

[All-Bidness]

Again, I see you've posted several times, why do we have to wait until tomorrow? What is the catalyst?

[Gasman47]

Your logic is flawed. You assume that the placebo group stays within their (your) defined group of mortality rates. In fact, the critical/excluded group with the higher mortality had passed thru the lesser mortality rate group on their way to the more critical group. They obviously would have been part of the sever/critical group that could have been inserted into the trial if they had the chance to. The placebo group no doubt had recoveries but they also had progression into a more critical/excluded group, and then unfortunately would have the greater than 32% mortality. Leronlimab’s challenge is to keep the severe/critical group from going into the more critical group that would have the higher mortality. This is where the results will either show LL works or doesn’t.
So your inference that the Plcebo group would have a lower mortality rate is clearly flawed.